A CD19×CD3 bispecific antibody that binds CD3 on T cells and CD19 on B cells to redirect T‑cell cytotoxicity and deplete CD19+ B-lineage cells; administered IV or SC.
Bispecific antibody that binds CD3 on T cells and CD19 on B cells to crosslink and activate T cells, redirecting cytotoxicity to CD19+ B-lineage cells and depleting them.
NO
INDIRECT
A-319 engages CD3 on T cells to activate and redirect them to kill CD19+ B cells; CD3ε-expressing T cells are not killed but mediate perforin/granzyme-dependent cytotoxicity against CD19+ targets.
Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.
Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.
YES
DIRECT
Polyclonal antibodies in ATG bind CD45 on T cells, activating complement and Fc-mediated effector functions (ADCC and phagocytosis) to deplete the bound cells.
Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.
Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.
YES
DIRECT
ATG contains antibodies that bind CD11a (LFA-1) on T cells and deplete them via complement-dependent lysis and Fc-mediated effector functions (ADCC by NK cells and phagocytosis).
Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.
Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.
NO
INDIRECT
ATG does not target HLA‑DR; it binds multiple T‑cell antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis.
Anti-CD20 monoclonal antibody used for B-cell depletion to reduce humoral alloimmunity.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing humoral alloimmunity.
YES
DIRECT
Anti-CD20 antibody binds CD20 on B cells and kills via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (via FcγR effector cells), and apoptosis signaling.